New Microbes and New Infections最新文献

{"title":"Mixta calida, not only an environmental bacterium, but a potential opportunistic threat: Case report of an osteitis with skin necrosis and mini review of the literature","authors":"Laurent Blairon ,&nbsp;Johnatan Everaert ,&nbsp;Bruno Baillon ,&nbsp;Sophie Collignon ,&nbsp;François Coenen ,&nbsp;Roberto Cupaiolo ,&nbsp;Ingrid Beukinga ,&nbsp;Marie Tré-Hardy","doi":"10.1016/j.nmni.2024.101524","DOIUrl":"10.1016/j.nmni.2024.101524","url":null,"abstract":"<div><h3>Background</h3><div><em>Mixta calida</em>, previously known as <em>Pantoea calida</em>, is an environmental bacterium rarely associated with human pathologies. Rare case reports mention sepsis, meningitis and implantable defibrillator infection.</div></div><div><h3>Case presentation</h3><div>A 67-year-old female with multiple comorbidities was referred to the emergency room for a comminuted fracture of both right tibial plateaus secondary to a fall and for which she benefited from an external fixator. After removal of the fixator, failure of osteosynthesis and placement of a new fixator, a skin necrosis appeared and a propeller distal anteromedial thigh perforator flap was performed. After 6 weeks, she presented a necrosis of the flap and an osteitis. The bone biopsy was positive with pure <em>M. calida</em>. The patient underwent an above-knee amputation, but 6 weeks later the wound was dehiscent and again positive with pure <em>M. calida</em>.</div></div><div><h3>Conclusions</h3><div>Serious infections due to <em>M. calida</em> are uncommon but can occur in immunocompromised patients. This case illustrates the first reported osteitis and skin necrosis due to <em>M. calida</em>.</div></div>","PeriodicalId":38074,"journal":{"name":"New Microbes and New Infections","volume":"62 ","pages":"Article 101524"},"PeriodicalIF":2.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Convalescent plasma therapy for COVID-19 – Donor selection strategies and establishment of a plasma bank","authors":"Mikael Kajova ,&nbsp;Tamim Khawaja ,&nbsp;Iris Levonen ,&nbsp;Jukka-Pekka Pietilä ,&nbsp;Jenni Virtanen ,&nbsp;Sari H. Pakkanen ,&nbsp;Hanna Välimaa ,&nbsp;Arttu Nousiainen ,&nbsp;Jussi Hepojoki ,&nbsp;Tarja Sironen ,&nbsp;Antti Vierikko ,&nbsp;Jarkko Ihalainen ,&nbsp;Olli Vapalahti ,&nbsp;Anu Kantele","doi":"10.1016/j.nmni.2024.101525","DOIUrl":"10.1016/j.nmni.2024.101525","url":null,"abstract":"<div><h3>Background</h3><div>Early in the COVID-19 pandemic, convalescent plasma (CP) emerged as a potentially effective treatment neutralising SARS-CoV-2. Early CP therapy with high neutralising antibody (NAb) titre may benefit COVID-19 outpatients and, in sufficient quantities even some hospitalised patients. This study details the process of setting up a CP bank, containing high- and low-titre CP for a clinical trial.</div></div><div><h3>Study design and methods</h3><div>We identified 18–65-year-old convalescents with SARS-CoV-2 NAb titres of ≥1:40 in microneutralisation test (MNT). Following eligibility pre-screening, the Finnish Red Cross Blood Service (FRCBS) determined suitability as CP donors.</div></div><div><h3>Results</h3><div>Of the 6466 COVID-19 convalescents contacted, 1481 provided serum, with 851 (57.5 %) exhibiting NAb titres ≥1:40. Participation barriers included reluctance, advanced age and, for women, insufficient body size. Of the volunteers, 125 were evaluated at FRCBS, with major exclusions for HLA antibodies (42 women), interferon antibodies (five men), and NAb titres waning below 1:20 (16 participants). Finally, 70 underwent plasmapheresis, resulting in 50 suitable CP donors (0.8 % of initial contacts and 3.4 % of those tested for NAb).</div></div><div><h3>Discussion</h3><div>The process of setting up a CP bank proved challenging. Excessive laboratory workloads during a pandemic hamper their ability to conduct MNT, underscoring the need for rapid screening tests. Only a small proportion of our convalescents exhibited high-titre CP, this fraction declining over time because of waning immunity. Strict plasmapheresis criteria further constrained donor eligibility. Establishing a plasma bank requires meticulous planning to maximize efficiency. Detailed insights from current experiences may prove critical in future pandemics before other remedies and vaccines become available.</div></div>","PeriodicalId":38074,"journal":{"name":"New Microbes and New Infections","volume":"62 ","pages":"Article 101525"},"PeriodicalIF":2.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142663747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First human infection with influenza A(H1N1) variant virus in Vietnam","authors":"Nitin Kumar Bansal,&nbsp;Sanjit Sah,&nbsp;Muhammed Shabil,&nbsp;Amogh Verma,&nbsp;Rodrigue Ndabashinze","doi":"10.1016/j.nmni.2024.101519","DOIUrl":"10.1016/j.nmni.2024.101519","url":null,"abstract":"","PeriodicalId":38074,"journal":{"name":"New Microbes and New Infections","volume":"62 ","pages":"Article 101519"},"PeriodicalIF":2.9,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142572292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fighting the Monkeypox in Rwanda, An overview of current state and future recommendations","authors":"Amos Kipkorir Langat,&nbsp;Maher Ali Rusho,&nbsp;Elysée Byiringiro,&nbsp;Godfred Yawson Scott,&nbsp;Amidu Alhassan,&nbsp;Vérité K. Cyubahiro,&nbsp;Christian Tague,&nbsp;Elie Kihanduka,&nbsp;Menelas Nkeshimana,&nbsp;Aymar Akilimali","doi":"10.1016/j.nmni.2024.101518","DOIUrl":"10.1016/j.nmni.2024.101518","url":null,"abstract":"","PeriodicalId":38074,"journal":{"name":"New Microbes and New Infections","volume":"62 ","pages":"Article 101518"},"PeriodicalIF":2.9,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142572229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bacteria vs bacteria; the future of antibiotics?","authors":"Muhammad Sohaib Khan,&nbsp;Kamran Ahmed Khan,&nbsp;Muhammad Jansher","doi":"10.1016/j.nmni.2024.101523","DOIUrl":"10.1016/j.nmni.2024.101523","url":null,"abstract":"","PeriodicalId":38074,"journal":{"name":"New Microbes and New Infections","volume":"62 ","pages":"Article 101523"},"PeriodicalIF":2.9,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re-emergence of Eastern equine encephalitis: A looming threat in the era of climate change","authors":"Amogh Verma,&nbsp;Vinay Suresh,&nbsp;Manvinder Brar,&nbsp;Amit Varma,&nbsp;Sanjit Sah,&nbsp;Mahendra Pratap Singh,&nbsp;Rachana Mehta,&nbsp;Ashok Kumar Balaraman,&nbsp;Sakshi Pandey,&nbsp;Sai Gautham Kanagala","doi":"10.1016/j.nmni.2024.101521","DOIUrl":"10.1016/j.nmni.2024.101521","url":null,"abstract":"","PeriodicalId":38074,"journal":{"name":"New Microbes and New Infections","volume":"62 ","pages":"Article 101521"},"PeriodicalIF":2.9,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142663749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series","authors":"Shuichi Abe ,&nbsp;Dhammika Leshan Wannigama ,&nbsp;Yu Suzuki ,&nbsp;Daisuke Akaneya ,&nbsp;Junko Igarashi ,&nbsp;Mayu Suto ,&nbsp;Kazunori Moriya ,&nbsp;Daisuke Ishizawa ,&nbsp;Yoshikazu Okuma ,&nbsp;Parichart Hongsing ,&nbsp;Cameron Hurst ,&nbsp;Thammakorn Saethang ,&nbsp;Paul G. Higgins ,&nbsp;Stephen M. Stick ,&nbsp;Anthony Kicic","doi":"10.1016/j.nmni.2024.101522","DOIUrl":"10.1016/j.nmni.2024.101522","url":null,"abstract":"<div><h3>Background</h3><div>Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.</div></div><div><h3>Methods</h3><div>This retrospective study evaluated 18 vaccinated outpatients (15 men; median age, 39.5 years; range, 26–56), treated with a 5-day oral ensitrelvir regimen (375 mg loading dose, followed by 125 mg daily) between December 1, 2022, and January 31, 2023. Nasal swabs were collected on days 0, 3, 6, and 9 for RT-qPCR to assess viral load. Variants were identified by Sanger sequencing, and outcomes were compared to historical controls. Patients were followed for 60 days to monitor for post-acute sequelae of COVID-19 (PASC).</div></div><div><h3>Results</h3><div>Symptoms such as mild fever and sore throat improved rapidly after one day of ensitrelvir treatment, with 66 % of patients recovering within six days. All individuals were infected with the BA.5 Omicron variant. Viral loads, as measured by Ct values, increased significantly from 21.82 at symptom onset to 37.65 b y day 6, with SARS-CoV-2 RNA undetectable in most patients by day 9. Those treated within 48 h of symptom onset showed the viral load reduction. Compared to historical controls, where symptom resolution took 8.5 days, ensitrelvir shortened recovery time to as little as 1.4 days for over 66 % of patients.</div></div><div><h3>Conclusion</h3><div>Ensitrelvir treatment resulted in rapid symptom relief and significant viral load reduction, with no adverse events, viral rebound, or PASC symptoms, demonstrating its potential efficacy and safety. Larger studies are needed for further confirmation.</div></div>","PeriodicalId":38074,"journal":{"name":"New Microbes and New Infections","volume":"62 ","pages":"Article 101522"},"PeriodicalIF":2.9,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142572228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic variability of the recombinant SARS-CoV-2 XEC: Is it a new evolutionary dead-end lineage?","authors":"Francesco Branda,&nbsp;Massimo Ciccozzi,&nbsp;Fabio Scarpa","doi":"10.1016/j.nmni.2024.101520","DOIUrl":"10.1016/j.nmni.2024.101520","url":null,"abstract":"","PeriodicalId":38074,"journal":{"name":"New Microbes and New Infections","volume":"62 ","pages":"Article 101520"},"PeriodicalIF":2.9,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new and more contagious XEC subvariant of SARS-CoV-2 may lead to massive increase in COVID-19 cases","authors":"Aminath Waafira,&nbsp;Kannan Subbaram,&nbsp;Razana Faiz,&nbsp;Zeba Un Naher,&nbsp;Punya Laxmi Manandhar,&nbsp;Sheeza Ali","doi":"10.1016/j.nmni.2024.101517","DOIUrl":"10.1016/j.nmni.2024.101517","url":null,"abstract":"","PeriodicalId":38074,"journal":{"name":"New Microbes and New Infections","volume":"62 ","pages":"Article 101517"},"PeriodicalIF":2.9,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142535479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of clade-defining single nucleotide polymorphisms for improved rabies virus surveillance","authors":"Ankeet Kumar,&nbsp;Sheetal Tushir,&nbsp;Yashas Devasurmutt,&nbsp;Sujith S. Nath,&nbsp;Utpal Tatu","doi":"10.1016/j.nmni.2024.101511","DOIUrl":"10.1016/j.nmni.2024.101511","url":null,"abstract":"<div><h3>Background</h3><div>Rabies is an ancient disease that remains endemic in many countries. It causes many human deaths annually, predominantly in resource-poor countries. Over evolutionary timelines, several rabies virus (RABV) genotypes have stabilised, forming distinct clades. Extensive studies have been conducted on the origin, occurrence and spread of RABV clades. Single nucleotide polymorphisms (SNPs) distribution across the RABV genome and its clades remains largely unknown, highlighting the need for comprehensive whole-genome analyses.</div></div><div><h3>Methods</h3><div>We accessed whole genome sequences for RABV from public databases and identified SNPs across the whole genome sequences. Then, we annotated these SNPs using an R script, and these SNPs were categorised into different categories; universal, clade-specific, and clade-defining, based on the frequency of occurrence.</div></div><div><h3>Results</h3><div>In this study, we present the SNPs occurring in the RABV based on whole genome sequences belonging to 8 clades isolated from 7 different host species likely to harbour dog-related rabies. We classified mutations into several classes based on their location within the genome and assessed the effect of SNP mutations on the viral glycoprotein.</div></div><div><h3>Conclusions</h3><div>The clade-defining mutations have implications for targeted surveillance and classification of clades. Additionally, we investigated the effects of these mutations on the Glycoprotein of the virus. Our findings contribute to expanding knowledge about RABV clade diversity and evolution, which has significant implications for effectively tracking and combatting RABV transmission.</div></div>","PeriodicalId":38074,"journal":{"name":"New Microbes and New Infections","volume":"62 ","pages":"Article 101511"},"PeriodicalIF":2.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142535474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}